Pharma manager bets on post-vaccine hike in routine health appointments

While active health care investor Fondita banks on medical needs in the post-Covid-19 world, the first portfolio review after the pandemic's onset will be carried out in December at Seligson's passively managed pharmaceutical fund. "We are trying to interpret what will happen in the markets after there is a vaccination," Fondita's CEO says.

Photo: Pexels

Following a go-ahead from safety watchdogs to resume clinical trials for a Covid-19 vaccine candidate on Sunday, the share price of British-Swedish drugmaker AstraZeneca has experienced steady increase since Monday. The same day Pfizer announced it is likely the US will deploy a Covid-19 shot before the end of the year.

At Finnish asset manager Seligson, some 3.57 percent of the company's Global Top 25 Pharmaceutical funds and Fondita’s Healthcare fund 3.6 percent of portfolio is invested in AstraZeneca.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Further reading

Related articles

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch